GLP3-RT 30mg (Retatrutide, also referenced as LY3437943) is a high-purity synthetic investigational peptide supplied by Echo Peptides strictly for in-vitro laboratory research. Sourced from qualified production channels, it is engineered as a single molecule that simultaneously targets three receptors — the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor.
As a triple-receptor reference compound, Retatrutide gives researchers a clean signal for probing how convergent incretin and glucagon pathways behave in cell-culture and preclinical systems. Its structural modifications, including a fatty acid conjugate, are intended to support stability in research models, making it a useful tool compound for studies comparing single-, dual-, and triple-agonist signaling.
Key research areas
- Multi-receptor metabolic and energy-expenditure models
- Glucose homeostasis and appetite-regulation pathways
- Lipid metabolism and weight-management paradigms in preclinical models
- Advanced incretin and glucagon signaling studies across GIP, GLP-1, and glucagon receptors
Specifications
- Amount: 30mg
- Form: Lyophilized white powder
- Modifications: Triple agonist with fatty acid conjugate
- Solubility: Soluble in bacteriostatic water for research use
- Storage: Refrigerate at 2–8°C; long-term stability when lyophilized
- Quality: Third-party tested for identity and purity; a Certificate of Analysis is available for each batch
GLP3-RT 30mg is intended for in-vitro laboratory research use only. It is not for human or veterinary use and is not for diagnostic or therapeutic purposes.
